Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bipolar disorder
Pharma
Intra-Cellular closing in on major depression nod for Caplyta
Intra-Cellular's surging antipsychotic Caplyta has scored again with remarkable trial results, fueling its bid for its third indication—depression.
Kevin Dunleavy
Jun 18, 2024 11:40am
15 years later, Vanda secures another FDA nod for Fanapt
Apr 3, 2024 11:04am
Alkermes reports strong trajectory for Lybalvi, shares up 10%
Feb 15, 2024 1:10pm
Intra-Cellular re-ups winning ad as bipolar drug builds momentum
Aug 8, 2023 12:51pm
New Alkermes ad wants Lybalvi to help patients 'push back'
Jun 7, 2023 9:20am
FDA signs off on Otsuka and Lundbeck's longer-acting Abilify
Apr 28, 2023 11:00am
